Advertisements



We are Sorry, This Page doesn't Exist


North Texas biotech settles litigation over ADHD drug

Grand Prairie-based Neos Therapeutics Inc. entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA Inc. to resolve all ongoing litigation involving Neos' patents for its Cotempla product. The two companies got .....»»

Category: topSource: bizjournalsDec 27th, 2018

Why G1 Therapeutics Got Hammered 42.6% Today

What happened G1 Therapeutics NASDAQ GTHX reported phase 2 trial data on its lead drug candidate that failed to inspire investor optimism and shares crashed 42 6 on Thursday So what The company is developing trilaciclib a cell preserving drug it hopes.....»»

Category: futuresSource: nasdaqDec 20th, 2018

Cara Therapeutics Stock Could Outperform in 2019

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CARA stock could be meaningfully boosted by drug development updates in 2019 The post Cara Therapeutics Stock Could Outperform in 2019 appeared first on InvestorPlace......»»

Category: topSource: investorplaceDec 19th, 2018

Protagonist Therapeutics begins Phase 1 trial of inflammatory bowel disease drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 13th, 2018

Akari Therapeutics to present Coversin data at Drug Development Summit

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 15th, 2018

Mirati Therapeutics stock drops 30% premarket after cancer trial results

Mirati Therapeutics Inc. shares dropped 30% in Monday premarket trade after the company presented results from a phase 2 trial in which its cancer drug sitravatinib was combined with Bristol-Myers Squibb Co.'s cancer drug Opdivo . The trial enrolled p.....»»

Category: topSource: marketwatchOct 22nd, 2018

Viking Shares Jump After Fatty Liver Drug Meets Midstage Trial Endpoints

Viking Therapeutics Inc (NASDAQ: VKTX) shares have raced away Tuesday following the read more.....»»

Category: blogSource: benzingaSep 18th, 2018

Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall

The company’s midstage clinical trial had positive results, and the condition in question affects an estimated 100 million people in the U.S......»»

Category: topSource: marketwatchSep 18th, 2018

Juno Therapeutics and investors reach settlement related to fatal drug trial

The $24 million mediated settlement stems from a string of patient deaths that nearly derailed Seattle's star biotech startup two years ago......»»

Category: topSource: bizjournalsSep 2nd, 2018

Ovid Therapeutics shares fall 28% as investors question new drug data (OVID)

Markets Insider New York-based biotech company Ovid Therapeutics announced on Monday positive phase 2 trial results for its treatment for a rare disease called Angelman Syndrom.....»»

Category: topSource: businessinsiderAug 6th, 2018

Mersana Therapeutics shares plummet 40% after patient death in cancer trial

Mersana Therapeutics Inc. said early Thursday that, after the company reported a patient death in its cancer drug trial, the Food and Drug Administrat.....»»

Category: topSource: marketwatchJul 19th, 2018

Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are pushing northward on over five times their average volume after the company reported positive results from an ongoing midstage trial. read more.....»»

Category: blogSource: benzingaJul 17th, 2018

Global Blood Therapeutics is making a big gamble on its sickle cell drug

The company is betting that recent trial results, which were mostly positive, are enough to score a drug approval — and is pausing the trial......»»

Category: topSource: marketwatchJun 27th, 2018

Global Blood Therapeutics is gambling on its sickle cell drug — and investors aren’t happy

The results, which were mostly positive, should have pleased investors. But the company is betting they are enough to score a drug approval — and is pausing the trial......»»

Category: topSource: marketwatchJun 27th, 2018

Cara Therapeutics Rallies On Positive Opioid Receptor Agonist Trial Results

Cara Therapeutics Inc (NASDAQ: CARA) popped more than 32 percent Wednesday morning after management reported positive top-line data for a drug candidate.  read more.....»»

Category: blogSource: benzingaJun 27th, 2018

Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment

Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»

Category: topSource: marketwatchJun 27th, 2018

Nektar Plummets Amid Concern Over Cancer-Drug Trial Results

Nektar Therapeutics lost a third of its value in Monday trading after response rates in melanoma and kidney cancer patients decreased in a mid-stage trial of the company’s cancer drug in combination with Bristol-Myers Squibb Co.’s Opdivo......»»

Category: topSource: moneycentralJun 4th, 2018

CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial

Cambridge startup CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals said on Wednesday that the FDA has put on hold a highly anticipated upcoming trial of their experimental gene editing drug for sickle cell disease. CRISPR (Nasdaq: CRIS.....»»

Category: topSource: bizjournalsMay 30th, 2018

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Esperion Therapeutics shares were halted in premarket trading on Wednesday after the firm announced late-stage trial results for its cholesterol drug......»»

Category: blogSource: 247wallstMay 23rd, 2018

Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2018